Rituximab is noninferior to ocrelizumab in suppressing T2-weighted MRI lesions from month 6 to 24
Trial shows rituximab works as well as ocrelizumab for MS
This Phase 3 randomized controlled trial of 218 adults with newly diagnosed relapsing multiple sclerosis found rituximab noninferior to ocre…
A new study finds that two different treatments for multiple sclerosis show similar success in stopping brain lesions and managing disease a…
Refractory mastoiditis may signal granulomatosis with polyangiitis: case highlights need for early ANCA testing
Mastoiditis May Be Linked to Granulomatosis with Polyangiitis
A case report and literature review describes a 69-year-old woman with refractory mastoiditis later diagnosed as granulomatosis with polyang…
A persistent ear infection in an older patient revealed a rare underlying autoimmune condition called granulomatosis with polyangiitis.
Dupilumab as an off-label adjunctive approach facilitates corticosteroid minimization in severe pemphigus vulgaris
New approach helps manage severe skin disease with fewer steroids
This case report describes the use of dupilumab as an off-label adjunctive corticosteroid-minimizing approach for a patient with severe muco…
A new way to treat a severe blistering skin disease may help patients who cannot safely take high doses of steroids.
JAK and IL-6 inhibitors outperform TNF inhibitors for activity limitation in rheumatoid arthritis
Specific Biologic Drugs Show Better Results for Rheumatoid Arthritis
This meta-analysis of 99 studies evaluated patient-reported outcomes (PROs) in patients with rheumatoid arthritis treated with b/tsDMARDs. T…
New analysis shows that certain types of biologic drugs may better reduce activity limits and improve mental health for people with rheumato…
Rituximab plus lenalidomide provides comparable progression-free survival to rituximab-based immunochemotherapy in advanced follicular lymphoma
Trial shows lenalidomide and rituximab for advanced follicular lymphoma
This Phase 3 randomized controlled trial of 1030 patients with previously untreated advanced follicular lymphoma found that the combination …
A large trial shows that a combination of two drugs can serve as an effective alternative to chemotherapy for patients with advanced follicu…
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Venetoclax-based combinations show superior progression-free survival compared to chemoimmunotherapy in CLL without TP53 aberrations
Trial shows venetoclax combinations improve progression-free survival in CLL
This Phase 3 randomized controlled trial of 926 patients with CLL without TP53 aberrations found that venetoclax-based regimens (RV, GV, and…
New clinical trial results show that specific venetoclax combinations can keep chronic lymphocytic leukemia stable for longer than standard …
Bendamustine and rituximab treatment for Waldenström macroglobulinemia with renal AL amyloidosis shows hematologic response
New treatment approach shows promise for rare blood cancer
This case report describes a 71-year-old woman with Waldenström macroglobulinemia and renal AL amyloidosis treated with bendamustine plus ri…
A new drug combination helped a patient with a rare blood cancer and kidney issues, but it requires very careful monitoring.
Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy
New Strategies Target Treatment Resistance in Membranous Nephropathy
This systematic review examines the multifactorial mechanisms of rituximab resistance in patients with primary membranous nephropathy. It id…
Researchers identify new ways to treat primary membranous nephropathy when standard rituximab treatments do not work.
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …